Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer
- 26 April 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 15 (5) , 457-465
Abstract
Purpose. Most guidelines for hormone receptor (HR)–positive early breast cancer recommend addition of adjuvant chemotherapy for most women, leading to overtreatment, which causes considerable morbidity and cost. There has been recent incorporation of gene expression analysis in aiding decision making. We evaluated the cost-effectiveness of recurrence score (RS)–guided treatment using 21-gene assay as compared with treatment guided by the Adjuvant! Online program (AOL). Patients and Methods. A Markov model was developed to compare the cost-effectiveness of treatment guided either by 21-gene assay or by AOL in a 50-year-old woman with lymph node–negative HR-positive breast cancer over a lifetime horizon. We assumed that women classified to be at high risk all received chemotherapy followed by tamoxifen and those classified to be at low risk received tamoxifen only. The model took a health care payer's perspective with results reported in 2008 Canadian dollars ($). Event rates, costs, and utilities were derived from the literature. Both costs and benefits were discounted at 5%. Outcome measures were life years gained, quality-adjusted life years (QALYs), lifetime costs, and incremental cost-effectiveness ratios (ICERs). Results. For a 50-year-old woman, RS-guided treatment was associated with an incremental lifetime cost of $4,102 and a gain in 0.065 QALY, with an ICER of $63,064 per QALY compared with AOL-guided treatment. ICER increased with increasing cost of 21-gene assay and increasing age of patients. Results were most sensitive to probabilities relating to risk categorization and recurrence rate. Conclusions. The 21-gene assay appears cost-effective from a Canadian health care perspective.Keywords
This publication has 20 references indexed in Scilit:
- Systematic Review: Gene Expression Profiling Assays in Early-Stage Breast CancerAnnals of Internal Medicine, 2008
- Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in JapanBreast Cancer Research and Treatment, 2007
- Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100Breast Cancer Research and Treatment, 2007
- Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast CancerJournal of Clinical Oncology, 2003
- Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage Breast CancerJournal of the National Cancer Institute Monographs, 2001
- Computer Program to Assist in Making Decisions About Adjuvant Therapy for Women With Early Breast CancerJournal of Clinical Oncology, 2001
- Systematic Overview of Cost-Utility Assessments in OncologyJournal of Clinical Oncology, 2000
- Estimates of the lifetime costs of breast cancer treatment in CanadaEuropean Journal of Cancer, 2000
- Efficacy and Cost Effectiveness of Adjuvant Chemotherapy in Women with Node-Negative Breast CancerNew England Journal of Medicine, 1991
- A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive TumorsNew England Journal of Medicine, 1989